TOKYO, May 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the outcome of its strategy review.
In view of the current market conditions, the difficulty in raising
finance at the current low share price, and the problems associated with
the AD923 device which has necessitated a halt to the Phase III trials
Sosei has taken decisive action to cut costs, streamline its operation and
to secure the future of the business until it becomes a significant income
generating business from NVA237/QVA149 in a few years time.
- Sosei is closing its Chesterford operation and Sosei R&D's
continuing business will relocate to London in due course. This will
reduce UK headcount by c 40 staff and provide a full years cost saving of
- Sosei will no longer operate a drug discovery unit.
- Sosei R&D will maintain the rights to NVA237/QVA149 but seek
to out-license or sell all other assets generated in the UK including
AD923 and its discovery assets whilst seeking to retain some rights for
the Asian market.
- Tokyo will continue to develop Norlevo and explore other
This restructuring and portfolio review will provide Sosei with at least two years cash based on the post-restructuring cash burn including a budget allocation to explore some late stage product opportunities for future expansion but without the inclusion of any income from licensing or sales deals for its compounds.
Notes for Editors:
Sosei Group Corporation is a leading international biopharmaceutical
company with significant expertise in product discovery and development. It
has established a reduced risk business model primarily upon identifying
new uses for established drugs and exploiting its unique position within
Japanese, European and North American pharmaceutical mark
|SOURCE Sosei Group Corporation|
Copyright©2008 PR Newswire.
All rights reserved